Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia By Enhancing Common β Chain Cytokine Receptor Endocytosis

Blood (2021) 138 (Supplement 1): 59.

https://doi.org/10.1182/blood-2021-151559

Published: 2021

Journal Articles

Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib

Qian Yu, BS, Anna M Eiring, PhD, Matthew S. Zabriskie, Jamshid Khorashad, MD, PhD, David J Anderson, BS, Jade A Bryant, BS, Marc M Loriaux, MD, PhD, Jeffrey W Tyner, PhD, Thomas O'Hare, Michael W. Deininger

Blood (2011) 118 (21): 2481.

https://doi.org/10.1182/blood.V118.21.2481.2481

Published: 2011

Journal Articles

Intrinsic and Extrinsic Survival Signals Converge on STAT3 As a Critical Mediator of BCR-ABL-Independent Tyrosine Kinase Inhibitor Resistance,

Anna M Eiring, PhD, Ira L Kraft, BS, David J Anderson, BS, Elie Traer, MD, PhD, Qian Yu, BS, Jamshid Khorashad, MD, PhD, Thomas O'Hare, Michael W. Deininger

Blood (2011) 118 (21): 3742.

https://doi.org/10.1182/blood.V118.21.3742.3742

Published: 2011

Journal Articles

Frequency and Clonality of BCR-ABL Compound Mutations in Chronic Myeloid Leukemia,

Jamshid Khorashad, MD, PhD, Todd W. Kelley, MD, Philippe Szankasi, PhD, Lauren T. Adrian, Christopher A. Eide, Matthew S. Zabriskie, Thoralf Lange, MD, Ira L Kraft, BS, Anna M Eiring, PhD, Thomas O'Hare, Michael W. Deininger

Blood (2011) 118 (21): 3744.

https://doi.org/10.1182/blood.V118.21.3744.3744

Published: 2011

Journal Articles

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

Blood (2011) 118 (21): 3753.

https://doi.org/10.1182/blood.V118.21.3753.3753

Published: 2011

Journal Articles

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Dragana Milojkovic, MD, Gareth Gerrard, PhD, Christos Paliompeis, Marco Bua, MD, Alistair Reid, PhD, Mary Alikian, Jamshid Khorashad, MD, PhD, John M Goldman, David Marin, Letizia Foroni, MD PhD, Jane F Apperley, MBChB, MD, FRCP, FRCPath

Blood (2011) 118 (21): 605.

https://doi.org/10.1182/blood.V118.21.605.605

Published: 2011

Journal Articles

Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia

Ailsa Holroyd, MD, Elizabeth Phillips, MD, Richard Szydlo, PhD, David Marin, MD, PhD, Letizia Foroni, MD, PhD, Jamshid Khorashad, MD, PhD, Dragana Milojkovic, MD, PhD, Edward J. Kanfer, MD, Francesco Dazzi, Donald H. MacDonald, MD, PhD, Amin Rahemtulla, MBBS, PhD, FRCP, Donal McLornan, MD, PhD, Ian H Gabriel, MD, Jiri Pavlu, MD, Jeremy Sargent, MD, John M. Goldman, MD, PhD, Jane F. Apperley, MD, Katayoun Rezvani, MD, PhD

Blood (2010) 116 (21): 3515.

https://doi.org/10.1182/blood.V116.21.3515.3515

Published: 2010

Journal Articles

Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.

Alex Bazeos, Jamshid Khorashad, François-Xavier Mahon, Lina L Eliasson, Dragana Milojkovic, Marco Bua, Jane Apperley, Richard Szydlo, Kasia Kozlowski, Christos Paliompeis, Ritti Desai, Letizia Foroni, Alistair Reid, Hugues de Lavallade, Katy Rezvani, John Goldman, David Marin

Blood (2009) 114 (22): 3290.

https://doi.org/10.1182/blood.V114.22.3290.3290

Published: 2009

Journal Articles

Varying response to escalating the dose of imatinib in patients with CML who “acquire” a BCR-ABL M244V mutant allele

Mona Anand, Jamshid Khorashad, David Marin, Jane F. Apperley, John M. Goldman, Jaspal Singh Kaeda

Blood (2006) 108 (8): 2881–2882.

https://doi.org/10.1182/blood-2006-05-020859

Published: 2006

NARROW

MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia By Enhancing Common β Chain Cytokine Receptor Endocytosis

Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib

Intrinsic and Extrinsic Survival Signals Converge on STAT3 As a Critical Mediator of BCR-ABL-Independent Tyrosine Kinase Inhibitor Resistance,

Frequency and Clonality of BCR-ABL Compound Mutations in Chronic Myeloid Leukemia,

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia

Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.

Varying response to escalating the dose of imatinib in patients with CML who “acquire” a BCR-ABL M244V mutant allele

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only